MHRA says that amendments to the EU Commission Implementing Regulation 520/2012 took effect on 12 February 2026 and, although the UK operates an independent regulatory framework, the changes still have practical implications for some UK-authorised medicines, especially Category 2 products and products held by companies licensed in both the UK and EU.
That matters because pharmacovigilance compliance is often shaped by cross-border operational reality, not just headline legal independence. For organisations managing UK and EU portfolios together, even externally driven rule changes can affect how documents, oversight, and reporting expectations are handled internally. This is an inference from MHRA’s own explanation of the practical implications.
For compliance teams, the safest posture is not to assume that “UK separate from EU” automatically means “no operational impact.” In 2026, that assumption looks increasingly risky.
0 Comments